2010; 16:495-500 <http://www.molvis.org/molvis/v16/a55>
Received 19 December 2009 | Accepted 15 March 2010 | Published 23 March 2010
Elena Aller,1,2 Teresa Jaijo,1,2 Erwin van Wijk,3,4,5,6 Inga Ebermann,7 Ferry Kersten,3,4,5,6,8 Gema García-García,1 Krysta Voesenek,4 María José Aparisi,1 Lies Hoefsloot,4 Cor Cremers,3,6 Manuel Díaz-Llopis,9,10 Ronald Pennings,3,6 Hanno J. Bolz,7 Hannie Kremer,3,5,6 José M. Millán1,2
The first two authors contributed equally to this work
1Unidad de Genética, Hospital Universitario La Fe. Valencia, Spain; 2CIBER de Enfermedades Raras (CIBERER), Valencia, Spain; 3Dept Otorhinolaryngology, Head and Neck Surgery, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 4Dept Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 5Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen, Nijmegen, The Netherlands; 6Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen, Nijmegen, The Netherlands; 7Institute of Human Genetics, University Hospital of Cologne, Cologne, Germany; 8Dept Ophthalmology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 9Servicio de Oftalmología, Hospital Universitario La Fe, Valencia, Spain; 10Departamento de Oftalmología, Facultad de Medicina, Universidad de Valencia, Valencia, Spain
Correspondence to: Jose Millan, Hospital Universitario La Fe and CIBERER, Genetics Avda. Campanar, 21, Valencia, Spain 46009; Phone: +34 96 197 3153; FAX: +34 96 3089; email: email@example.com
Purpose: It has been demonstrated that mutations in deafness, autosomal recessive 31 (DFNB31), the gene encoding whirlin, is responsible for nonsyndromic hearing loss (NSHL; DFNB31) and Usher syndrome type II (USH2D). We screened DFNB31 in a large cohort of patients with different clinical subtypes of Usher syndrome (USH) to determine the prevalence of DFNB31 mutations among USH patients.
Methods: DFNB31 was screened in 149 USH2, 29 USH1, six atypical USH, and 11 unclassified USH patients from diverse ethnic backgrounds. Mutation detection was performed by direct sequencing of all coding exons.
Results: We identified 38 different variants among 195 patients. Most variants were clearly polymorphic, but at least two out of the 15 nonsynonymous variants (p.R350W and p.R882S) are predicted to impair whirlin structure and function, suggesting eventual pathogenicity. No putatively pathogenic mutation was found in the second allele of patients with these mutations.
Conclusions: DFNB31 is not a major cause of USH.
Usher syndrome (OMIM 276900–2; OMIM 276905; OMIM 605472) is the most common cause of genetic deafblindness. This syndrome follows an autosomal recessive pattern of inheritance and is characterized by retinitis pigmentosa (RP), sensorineural hearing impairment, and in some cases vestibular dysfunction. Three clinical types can be distinguished . Patients with Usher syndrome type I (USH1) show severe to profound congenital hearing loss, early onset RP, and vestibular areflexia. Patients with type II (USH2) suffer from moderate to severe congenital hearing loss, onset of RP around puberty or in adulthood, but normal vestibular function. Usher type III (USH3) patients present with progressive hearing loss, RP, and variable vestibular function. Furthermore, some Usher syndrome patients cannot be classified into any of these three subtypes and are considered atypical Usher (USHA) patients. To date, nine genes are known to be involved in USH: MYO7A (USH1B), USH1C, CDH23 (USH1D), PCDH15 (USH1F), and USH1G for USH1; USH2A, GPR98 (USH2C), and DFNB31 (USH2D) for USH2; and USH3A for USH3 [2-14]. The eight genes responsible for USH1 and USH2 encode proteins that interact in a functional network.
The DFNB31 gene was initially found to be responsible for recessive nonsyndromic sensorineural hearing impairment (NSHI), underlying the DFNB31 locus . DFNB31 comprises 12 exons and encodes the whirlin protein. Two isoforms of whirlin are known. The short isoform is encoded by exons 6–12 and contains one PDZ domain (PDZ3) and a proline-rich region. The long isoform is encoded by all 12 DFNB31 exons and contains three PDZ domains (PDZ1, PDZ2, and PDZ3) and a proline-rich region . PDZ1 and PDZ2 have been shown to interact with usherin, myosin VIIa, G-Protein coupled Receptor 98 (GPR98), Scaffold protein containing Ankyrin repeats and SAM domain (SANS), and myosin XVa, while PDZ3 interacts only with myosin XVa [16-18]. All these findings made DFNB31 an excellent candidate for Usher syndrome. More recently, Ebermann et al.  described a novel genetic subtype for Usher syndrome type II (USH2D) caused by truncating mutations in the long isoform of whirlin.
The protein whirlin is thought to play an important role in the elongation of stereocilia and development of cochlear hair cells and has been demonstrated to be the major scaffold protein of an Usher protein network in the ankle link complex of inner hair cells [15,17,19]. In the retina, whirlin is a key partner of another USH interactome in the periciliary region of photoreceptor cells. This Usher protein network is hypothesized to be essential for the regulation of cargo transfer from the photoreceptor inner segment to the outer segment by the ciliary transport system .
The recent finding that mutations in DFNB31 cause USH2 prompted us to screen the 12 exons of this gene in 195 patients from diverse origins who have USH1, USH2, and USHA. Our aim was to elucidate the prevalence of DFNB31 mutations in the pathogenesis of USH.
We included 149 patients with USH2, 29 patients with USH1, and six patients with USHA in this study. Furthermore, 11 unclassified USH patients were included from whom clinical data were not available. Of the 195 unrelated patients, 74 were of Spanish origin, 47 of German, 39 of Dutch, 17 of Hungarian, and 13 of other different origins (see Table 1).
Most of these patients were selected for DFNB31 screening after discarding the presence of pathologic mutations in the most prevalent USH genes. Of the 195 patients, 116 patients correspond to those briefly mentioned in previous studies [13,16]. Clinical diagnosis of Usher syndrome patients was performed in different hospitals according to standard ophthalmologic, otorhinolaryngologic, and electroretinographic procedures. Written informed consent was obtained for each participant, and the study was approved by the review board of the Ethics Committee of each institution that participated in this work.
Venous blood samples were obtained and genomic DNA was extracted by standard protocols . For mutation analysis of DFNB31, the 12 coding exons were PCR amplified using primers located in flanking introns and untranslated region (UTR) sequences (Table 2). PCR products were directly sequenced using standard procedures (Table 2). The obtained sequences were compared with the consensus sequence NM_015404.
Isocoding and missense changes found in a low frequency were analyzed with the program RESCUE-ESE (Christopher Burge Laboratory, Massachusetts Institute of Technology; Cambridge, MA). This program predicts the creation or elimination of exonic splicing enhancer sites (ESEs).
To assess the effect of the amino acid substitutions on the protein and to study the degree of interspecies amino acid conservation we used the software Alamut v1.5 Interactive Biosoftware (Rouen, France).
Intronic, isocoding, and missense changes were also analyzed using the programs NNSPLICE (Berkeley Drosophila Genome Project [BDGP] University of California Berkeley; Berkeley, CA) and Splice View (Institute of Biomedical Technologies, Milano, Italy) to predict if those changes could be affecting, creating, or eliminating donor/acceptor splice sites.
Mutation screening of DFNB31 in 195 USH patients of diverse origins identified 38 different sequence variants: eight synonymous, 15 missense, and 15 intronic variants. Most of these changes are clearly polymorphic as they were detected in high frequencies and represent known single nucleotide polymorphisms (SNPs). Twelve sequence variants were found only once in our series, five changes were found twice, one variant was identified in three alleles, and another one in four (see Table 3). None of these 19 rare changes were found in the homozygous state or in trans to another putatively pathogenic variation.
Only three out of the eight silent changes were found with an allele frequency ≤0.01 (see Table 3 for more details). Variant c.1486C>T was only found in one USH2 patient from uncertain origin, and c.2307C>T was found in one USH1 patient from Spain and in one USH2 patient from Germany. Variant c.1455G>A was detected in four alleles of patients from the Netherlands and Germany. These three rare isocoding variants were analyzed using the RESCUE-ESE program, but none were found to create or eliminate any ESEs.
These three changes were also analyzed with NNSPLICE and Splice View. Both programs predicted the creation of one new donor site when introducing the change c.2307C>T (NNSPLICE score of 0.66 [0.00–1.00] and Splice View score of 86 [0–100])
From the 15 missense variants detected, only p.T77S, p.R350W, p.T383N, p.T383S, p.D447H, p.S628R, p.S648Y, p.M723I, and p.R882S showed a frequency ≤0.01 (see Table 3).
These nine variants were analyzed using the Alamut program. For two of these changes (p.R350W and p.R882S), this program predicted possible implications in protein structure and function. The amino acid substitution p.R350W (c.1048C>T) affected a highly conserved nucleotide at the cDNA level with a score of 0.9 (0–1). The amino acid conservation among 13 species was moderate, and the Grantham distance between amino acids Arg and Trp was 101 (0–215). Furthermore, this variation was found to be located in the PDZ2 protein domain. The change p.R882S (c.2644C>A at the cDNA level) affects a highly conserved nucleotide (score 1.0 [0–1]) and an amino acid highly conserved up to the fruit fly (considering 13 species). The physicochemical difference between Arg and Ser was found to be moderate since a Grantham distance of 110 (0–215) was obtained. Also this variation was located in the PDZ3 domain.
These nine rare missense variants were further evaluated for an effect on exonic splice enhancers by using the RESCUE-ESE program. The change c.1148C>A (p.T383N), found in two unrelated USH2 patients from the Netherlands, creates four new putative ESE sites, whereas c.1339G>A (p.D447H), detected in one USH2 patient from Hungary, suppresses one existing ESE sequence and creates two new putative ESE sites. The remaining variants were not found to affect any ESE site.
These changes were also analyzed with NNSPLICE and Splice View, but neither was found to affect, create, or eliminate any donor or acceptor splice site.
All intronic variants were detected in frequencies ≥0.01, except for c.619–41A>G, c.837+41A>G, c.1203+114C>T, c.1416+62delC, c.2237–44C>T (rs766835), c.2419–16T>C, and c.2644–157C>T (Table 3). None of these changes were predicted to affect or create splice donor or splice acceptor sites in the analysis with the NNSPLICE and Splice View programs.
To date only one Usher family with clearly pathogenic, truncating, DFNB31 mutations has been described . Here, we describe additional sequence variants in USH patients tested for mutations in DFNB31 and discuss their putative pathologic effects.
A total of 38 different variants were found in the DFNB31 sequence, but no variant was a frameshift or a nonsense change. Out of these, 19 rare variants were found with allelic frequency ≤0.01; two of them were located in PDZ protein domains (p.R350W and p.R882S), and four were predicted to create or abrogate splice sites (c.2307C>T, p.T383N, p.D447H, and p.R882S).
By the introduction of p.R350W and p.R882S, uncharged amino acids may affect the three-dimensional structure of the protein, which is important for the adequate function of interacting domains. Furthermore, both the amino acids R350 and R882 were well conserved throughout evolution, indicating these residues have an important role in protein structure and function. All these factors point to a possible pathologic effect for these two variants.
Segregation analysis for the variants p.R350W, p.G769G, p.T383N, and p.D447H could not be performed. In some cases, we only had a DNA sample from a patient without any family history. In other cases, the patient was a sporadic case and segregation analysis did not reveal any information about the pathogenicity of the variant (e.g., in the case of p.R882S). We found variant p.R882S in a sporadic Spanish USH2 patient together with the variant p.S648Y. Segregation analysis for these changes was performed in healthy relatives and revealed that both variants were located on the same allele. In addition, p.R882S and p.S648Y were present in the patient, in his healthy brother and sister, and in his two healthy children.
To explore the possibility of yet unidentified exons of DFNB31, which may contain mutations in the second allele of patients with a potentially pathogenic mutation on one allele, we performed an in silico search by using Geneid (Genome Bioinformatics Research Lab; Center for Genomic Regulation, Barcelona, Spain), N-SCAN (Computational Genomics Laboratory; Washington University of St. Louis, St. Louis; MO) and we also searched in the UCSC Genome Browser (University of California Santa Cruz Genome Bioinformatics Web Site, Santa Cruz, CA), but no additional exons were predicted in the DFNB31 locus.
In summary, this study did not reveal evidence for the involvement of DFNB31 mutations in 195 unrelated USH patients. However, total or partial gene deletions and duplications can escape the screening method applied herein and therefore cannot be excluded. Our results indicate a minor causative role for DFNB31 in Usher syndrome. However, modifying effects of the variants we detected might contribute to the phenotype of Usher syndrome.
Regarding the implication of this gene in nonsyndromic hearing loss, the studies performed so far also indicate that DFNB31 is a rare form of deafness [15,20]. We previously hypothesized that DFNB31 mutations may also be causative for nonsyndromic retinal degenerations. This remains to be confirmed.
The authors are grateful to the participating patients and their relatives. Supported by grants BO 2954/1–1 (Deutsche Forschungsgemeinschaft), Koeln Fortune Program, grant 113/2004 (Faculty of Medicine, University of Cologne) and Forschung contra Blindheit – Initiative Usher Syndrom e.V. to H.J.B and Research Projects PI07/0558 and PI08/90311 (Institute of Health Carlos III, Spanish Ministry of Science), grant GR552 of the BRPS to H.K. and by the Forschung contra Blindheit – Initiative Usher Syndrome.V to H.K. Elena Aller, Teresa Jaijo and Jose M. Millán are members of the CIBER for Rare Diseases (CIBERER), an initiative of the Institute of Health Carlos III from the Spanish Ministry of Science and Innovation.